CClinicalTrials.gg
Active, not recruitingNCT06886022Updated Mar 20, 2025

Diagnosis, Treatment, and Prevention of Colorectal Cancer Amid Abnormal Lipid Metabolism

An observational study in Colorectal Cancer, sponsored by Tianjin Union Medical Center. Active, not recruiting. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Tianjin Union Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
20 Years to 80 Years
Sex
All
01

Study summary

This research project investigates the interplay between lipid metabolism, inflammation, and colorectal cancer (CRC). We are building a comprehensive database of CRC patients, incorporating clinical data, body composition measurements, imaging findings, and biomarkers related to lipid metabolism and inflammation. Our goal is to identify how these factors contribute to CRC development, progression, and perioperative outcomes. Ultimately, we aim to develop a digital, personalized "three-tier prevention" strategy encompassing early risk prediction, targeted interventions, and comprehensive rehabilitation for improved CRC patient care.

Read the detailed description

Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies worldwide, accounting for approximately 8% of all cancer cases [1]. Numerous epidemiological studies have identified obesity as a risk factor for CRC [2]. Abnormal fat distribution and lipid metabolism dysregulation contribute to a chronic, low-grade inflammatory state and increased oxidative stress, potentially triggering mutations, carcinogenesis, and tumor cell proliferation [3]. Research suggests that adipose tissue and its associated inflammatory factors may play a key role in the obesity-cancer link.

Regarding fat distribution, visceral adipose tissue exhibits higher metabolic activity compared to subcutaneous fat [4]. Excess visceral fat promotes insulin resistance and inflammatory pathways [5], potentially increasing CRC risk. Abnormal visceral fat distribution is also associated with postoperative complications, survival time, and the efficacy of adjuvant therapy in CRC patients [6]. Furthermore, non-alcoholic fatty liver disease (NAFLD), potentially representing a specific type or hepatic manifestation of abnormal fat distribution, is considered a risk factor for CRC.

Our research group previously conducted a retrospective study involving 93 patients undergoing gastrointestinal surgery (including CRC). We found that, compared to the group without perioperative weight loss, patients experiencing perioperative weight loss exhibited decreased serum albumin, elevated blood glucose, and elevated serum cholesterol. Multivariate regression analysis indicated that serum cholesterol was a risk factor for perioperative weight loss, showing a positive correlation.

Currently, we are conducting a small-scale study specifically focusing on CRC patients. By collecting perioperative data, including body composition, fat distribution, BMI, abdominal CT scans, inflammatory markers, and obesity-related indices, we aim to elucidate the roles of lipid metabolism, fat distribution, and related inflammatory factors in the development and progression of CRC, as well as their impact on perioperative adverse clinical outcomes. We have obtained promising preliminary results, establishing a foundation for digitizing our overall research findings.

This project aims to establish a research system correlating lipid metabolism, inflammation, and CRC. A CRC patient lipid metabolism database will serve as a platform to expand our previous study's sample size. By integrating and analyzing data from this platform, we will develop a digital, visualized "three-tier prevention" network for CRC, integrating a "digital vaccine" (predictive screening model), "digital drug" (intervention model targeting associated pathogenic mechanisms), and "digital rehabilitation" (preventive system combining early warning and treatment).

02

Conditions studied

  • Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Lipid Metabolism
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Tianjin Union Medical Center is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Age 20-80 years, confirmed CRC diagnosis

Inclusion criteria

  • Age 20-80 years, confirmed CRC diagnosis, consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Age \<20 or >80 years; inability to perform activities of daily living; presence of infectious diseases; lack of communication and cognitive abilities; refusal to participate in the study.
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observation

    Colorectal cancer patients after surgery

    Procedure: Colorectal cancer procedures

Interventions

  • ProcedureColorectal cancer procedures

    Procedures

06

What researchers measure

Primary outcomes

  1. Abdominal CT L3 level adipose tissue surface

    Abdominal CT L3 level adipose tissue surface

    Time frame: Preoperatively

  2. Abdominal CT L3 level skeletal muscle surface

    Time frame: Preoperatively

Secondary outcomes

  1. Tumor TNM stage

    Time frame: immediately after the procedure

  2. Overall Survival

    Time frame: 3 years

  3. Disease Free Survival

    Time frame: 3 years

  4. Hand grip strength

    Time frame: Preoperatively; Postoperatively Day 1,3,5,7

  5. Waist Circumference

    Time frame: Preoperatively

  6. Calf Circumference

    Time frame: Preoperatively; Postoperatively Day 1 3 5 7

  7. Progression Free Survival

    Time frame: 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06886022
Lead sponsor
Tianjin Union Medical Center
Responsible party
Jing Xu (Chief Physician, Tianjin Union Medical Center) — Principal investigator
First posted
Mar 20, 2025
Start date
Jan 1, 2017
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 20, 2025

Study contacts

Jing Xu, PhD
principal investigator · Tianjin Union Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion